Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

S. C. JOHNSON's FIBERALL SUGAR FREE, MD-PREFERRED CLAIMS

Executive Summary

S. C. JOHNSON's FIBERALL SUGAR FREE, MD-PREFERRED CLAIMS v. METAMUCIL have been adequately substantiated, the Better Business Bureaus Natl. Advertising Div. (NAD) concluded recently. Metamucil-mfr. Searle had challenged S. C. Johnmson/Rydelle Labs' advertising which showed the line's regular brand as "being 50% laxative fiber and 50% sugar by weight while Fiberall contained the same laxative fiber with added bran fiber." Ad claims in the campaign had declared: "Fiberall has the sugar-free formula preferred by three out of four doctors surveyed" and "instead of sugar, Fiberall gives you the extra benefit of another high fiber ingredient -- bran." In challenging the ads, Searle submitted a survey which it maintained "showed viewers would conclude that Fiberall contained more active ingredient than Metamucil and that Metamucil contained 50% sugar by volume," NAD said. Searle also noted that it makes Regular Metamucil in three forms, including a sugar-free version. To support the ad claim, S. C. Johnson told the council that Regular Flavor Metamucil is "49% psyllim fiber by weight and occupies 64% of a 14 oz. container" with the added sugar occupying 36% of the volume. S. C. Johnson said Fiberall "contains the same amount of psyllim, comprising 68% by weight or volume of a 10 oz. container" with added bran occupyin 32% of the container. "The advertiser maintained that its depiction of the two products with equal amounts of laxative by weight and its reference to the added natural or brain fiber in Fiberall could not be understood as claims for more of the active ingredient," NAD said. The bureau also said S. C. Johnson submitted results of two telephone surveys "demonstrating that doctors overwhelmingly favored a sugar free formula." "In its review, NAD found it "appropriate" for S. C. Johnson "to match its regular product against Regular Flavor Metamucil" since the product "outsells the remaining items in the Metamucil line." The report also noted that NAD had "questioned the implications of the sugar-free claim since Fiberall contained 2% sugar as a natural ingredient of the bran fiber and provides about 6 calories per dose compared with 14 calories for Metamucil." However, NAD said S. C. Johnson "maintained that its claim was not a claim for calorie savings but was directed to persons who are concerned about added sugar in processed foods and medications."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS008217

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel